Security
Imunon, Inc. Common Stock · IMNN
IMNNNASDAQCommon stockCurrentCIK 749647Updated Oct 29, 2026
Name history
CELSION CORP · through Sep 19, 2022Celsion CORP · through Sep 19, 2022CHEUNG LABORATORIES INC · through Feb 17, 1998
IMNN price & chart
Loading TradingView…
NASDAQ:IMNN on TradingView ↗About the company
Imunon is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.
In the news
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 ↗
Recent filings
S-1/A filing
S-1 filing
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 1.01, 3.02, 5.03, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 8,987,733Source | 14,391,190Source | 14,989,113Source | 8,788,327Source | 9,691,496Source | 8,018,713Source | 6,862,086Source | 14,324,768Source | 12,288,116Source | 9,717,364Source | 21,918,069Source | 43,975,894Source |
| Property, Plant and Equipment, NetUSD | 601,425Source | 563,602Source | 459,016Source | 676,565Source | 625,028Source | 459,936Source | 734,243Source | 693,360Source | 529,936Source | 541,272Source | 751,906Source | 548,301Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,250,929Source | 10,311,935Source | 6,864,378Source | 4,728,776Source | 5,306,568Source | 4,794,070Source | 2,871,756Source | 2,346,978Source | 8,781,059Source | 5,872,767Source | 5,838,566Source | 11,492,841Source |
| Accounts Receivable | — | — | — | — | — | — | — | — | —Source | —Source | —Source | —Source |
| Assets, CurrentUSD | 7,257,685Source | 12,532,406Source | 8,691,203Source | 6,891,245Source | 7,646,341Source | 6,620,885Source | 5,091,956Source | 12,094,343Source | 10,723,744Source | 8,008,959Source | 18,240,704Source | 37,154,691Source |
| Operating Lease, Right-of-Use AssetUSD | 1,078,623Source | 1,245,182Source | 788,894Source | 1,170,517Source | 1,370,127Source | 887,892Source | 985,887Source | 1,487,065Source | 984,436Source | 1,117,133Source | 1,595,074Source | 155,876Source |
| Other Assets, NoncurrentUSD | 1,128,623Source | 1,295,182Source | 5,838,894Source | 1,220,517Source | 1,420,127Source | 937,892Source | 1,035,887Source | 1,537,065Source | 1,034,436Source | 1,167,133Source | 2,925,459Source | 6,272,902Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,906,009Source | 6,199,469Source | 10,800,326Source | 6,128,477Source | 5,950,262Source | 4,659,082Source | 6,410,058Source | 5,825,025Source | 5,226,240Source | 5,473,066Source | 8,530,427Source | 14,648,028Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 28,963Source | 145,007Source | 46,657Source | 17,175Source | 94,009Source | 39,228Source | 146,207Source | 94,009Source | 34,197Source | 145,007Source | 93,998Source | 74,362Source |
| Additional Paid in CapitalUSD | 421,213,171Source | 410,877,721Source | — | 416,373,961Source | 401,632,757Source | 428,952,685Source | 411,296,548Source | 401,470,148Source | 428,410,939Source | 410,987,523Source | 401,500,838Source | 397,980,023Source |
| Retained Earnings (Accumulated Deficit)USD | -417,075,222Source | -402,745,819Source | -428,361,208Source | -413,646,098Source | -397,900,344Source | -425,547,094Source | -410,905,539Source | -393,112,327Source | -421,298,072Source | -406,803,044Source | -388,182,802Source | -368,667,825Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | 133,101Source | 0Source | — | 60,796Source | 26,494Source |
| Stockholders' Equity Attributable to ParentUSD | 4,081,724Source | 8,191,721Source | 4,188,787Source | 2,659,850Source | 3,741,234Source | 3,359,631Source | 452,028Source | 8,499,743Source | 7,061,876Source | 4,244,298Source | 13,387,642Source | 29,327,866Source |
| Liabilities and EquityUSD | 8,987,733Source | 14,391,190Source | 14,989,113Source | 8,788,327Source | 9,691,496Source | 8,018,713Source | 6,862,086Source | 14,324,768Source | 12,288,116Source | 9,717,364Source | 21,918,069Source | 43,975,894Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,197,912Source | 5,441,743Source | 4,778,846Source | 5,317,287Source | 5,077,352Source | 4,166,233Source | 5,796,887Source | 4,816,976Source | 4,623,829Source | 4,786,131Source | 7,391,134Source | 10,037,082Source |
| Operating Lease, Liability, CurrentUSD | 394,135Source | 508,450Source | 431,781Source | 382,217Source | 516,223Source | 418,903Source | 394,878Source | 500,625Source | 406,354Source | 452,358Source | 485,421Source | 230,749Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 3,515,192Source | 3,586,623Source |
| Operating Lease, Liability, NoncurrentUSD | 708,097Source | 757,726Source | 379,409Source | 811,190Source | 872,910Source | 492,849Source | 613,171Source | 1,008,049Source | 602,411Source | 686,935Source | 1,139,293Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,676,951Source | 2,573,430Source | 1,228,568Source | 3,199,502Source | 2,591,827Source | 2,782,740Source | 3,543,407Source | 1,958,575Source | 2,824,646Source | 3,033,747Source | 3,390,521Source | 4,794,936Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 5,300,000Source | 10,300,000Source | 6,900,000Source | 4,700,000Source | 5,300,000Source | 4,800,000Source | 2,900,000Source | 9,800,000Source | 8,800,000Source | 5,900,000Source | 15,700,000Source | 32,800,000Source |
| Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 5,964,280Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 9,796,291Source | 21,227,991Source |
| Preferred Stock, Value, Issued | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 407,000Source | 478,000Source | 472,000Source | 731,629Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 548,590Source | 204,533Source | 127,374Source | 477,256Source | 759,013Source | 2,673,034Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 1,280,385Source | 286,641Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,985,176Source | -2,847,051Source | -13,896,624Source | -18,854,970Source | -19,022,148Source | -23,131,376Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -259,652Source | -280,572Source | 9,828,733Source | 11,006,435Source | 8,315,278Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 259,652Source | 280,572Source | 29,541Source | 451,759Source | 267,800Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -1,813Source | 105,692Source | 17,085,488Source | 9,060,438Source | -3,638,562Source | 6,722,667Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,986,989Source | -3,001,011Source | 2,908,292Source | 34,201Source | -11,654,275Source | -8,093,431Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | — | 5,838,566Source | 17,492,841Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 179,542Source | 4,847,359Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 5,300,000Source | 10,300,000Source | 6,900,000Source | 4,700,000Source | 4,800,000Source | 2,900,000Source | 8,800,000Source | 5,900,000Source | 15,700,000Source | 32,800,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | 61,983Source | 431,801Source | -49,222Source |
| DepreciationUSD | — | — | — | — | — | — | 70,000Source | 66,681Source | 291,908Source | 240,175Source | 248,154Source | 197,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | 61,983Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | -329,158Source | — |
| General and Administrative ExpenseUSD | — | — | 1,576,577Source | 1,668,258Source | 1,326,891Source | 1,540,910Source | 1,969,244Source | 1,980,207Source | 6,869,996Source | 7,493,035Source | 9,742,739Source | 13,687,899Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | -1,280,385Source | -1,567,026Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,429,124Source | -4,845,475Source | -2,814,114Source | -2,740,559Source | -4,249,022Source | -4,102,495Source | -14,495,028Source | -18,620,242Source | -19,514,977Source | -35,898,234Source |
| Nonoperating Income (Expense)USD | — | — | 46,704Source | 115,992Source | -22,568Source | 27,305Source | — | — | 155,666Source | 512,204Source | 235,068Source | -12,543,695Source |
| Operating ExpensesUSD | — | — | 3,475,828Source | 4,961,467Source | 2,791,546Source | 2,767,864Source | 4,306,552Source | 4,145,299Source | 14,650,694Source | 19,132,446Source | 21,030,430Source | 25,421,565Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 5,500,000Source | — | 1,815,267Source | 4,797,848Source | 105,692Source | 13,628,070Source | 9,060,438Source | 2,781,438Source | 6,722,667Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | -34,302Source | — |
| Derivative, Gain (Loss) on Derivative, Net | — | — | — | — | —Source | — | — | — | — | — | — | — |
| InterestExpenseNonoperating | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Payments for Repurchase of Warrants | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 500,000Source |
| Operating Income (Loss)USD | — | — | -3,475,828Source | -4,961,467Source | -2,791,546Source | -2,767,864Source | -4,306,552Source | -4,145,299Source | -14,650,694Source | -19,132,446Source | -21,030,430Source | -24,921,565Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 14,500,000Source | -18,620,242Source | -20,795,362Source | -37,465,260Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | -1,280,385Source | -1,567,026Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,429,124Source | -4,845,475Source | -2,814,114Source | -2,740,559Source | -4,249,022Source | -4,102,495Source | -14,495,028Source | -18,620,242Source | -19,514,977Source | -35,898,234Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.16Source | -3.76Source | -0.54Source | -2.15Source | -0.84Source | -3.15Source | -6.83Source | -1.62Source | -2.16Source | -5.03Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.16Source | -3.76Source | -0.54Source | -2.15Source | -0.84Source | -3.15Source | -6.83Source | -1.62Source | -2.16Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 2,943,655Source | 1,289,823Source | 5,232,625Source | 1,277,217Source | 5,028,764Source | 1,300,944Source | 2,123,344Source | 11,508,159Source | 9,045,320Source | 7,142,970Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 2,943,655Source | 1,289,823Source | 5,232,625Source | 1,277,217Source | 5,028,764Source | 1,300,944Source | 2,123,344Source | 11,508,159Source | 9,045,320Source | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | 240,000Source | 248,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | 61,983Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,576,577Source | 1,668,258Source | 1,326,891Source | 1,540,910Source | 1,969,244Source | 1,980,207Source | 6,869,996Source | 7,493,035Source | 9,742,739Source | 13,687,899Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 197,080Source | 5,028,618Source |
| Investment Income, NetUSD | — | — | 46,704Source | 115,992Source | 32,518Source | 27,305Source | 57,530Source | 42,804Source | 155,666Source | 512,204Source | 1,157,625Source | 453,356Source |
| Nonoperating Income (Expense)USD | — | — | 46,704Source | 115,992Source | -22,568Source | 27,305Source | — | — | 155,666Source | 512,204Source | 235,068Source | -12,543,695Source |
| Operating ExpensesUSD | — | — | 3,475,828Source | 4,961,467Source | 2,791,546Source | 2,767,864Source | 4,306,552Source | 4,145,299Source | 14,650,694Source | 19,132,446Source | 21,030,430Source | 25,421,565Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | -396,319Source | 1,801Source |
| Research and Development ExpenseUSD | — | — | 1,899,251Source | 3,293,209Source | 1,464,655Source | 1,226,954Source | 2,337,308Source | 2,165,092Source | 7,780,698Source | 11,639,411Source | 11,287,691Source | 11,733,666Source |
| Interest Expense (non-operating) | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Preferred Stock Dividends, Income Statement Impact | — | — | — | — | —Source | — | — | — | — | — | — | — |
Offerings
Registration 333-299647
Registration 333-287699
Registration 333-286403
Filing attachments
ex4-10.htm · S-1/A · 2026-10-28
Exhibit 4.10 Imunon, Inc. PLACEMENT AGENT SHARE PURCHASE WARRANT Warrant No. [_] Number of Warrant Shares or Exchange Warrants: [_] Date of Issuance: [_], 2026 (the “ Issuance Date ”) Imunon, Inc., a Delaware corporation (the “ Company ”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [Maxim Partners LLC], the registered holder hereof or its permitted assigns (the “ Holder ”), is entitled, subject to the terms and …
Read attachment ↗ex4-8.htm · S-1/A · 2026-10-28
Exhibit 4.8 FORM OF TRANCHE [A][B][C][D] WARRANT 1 TO PURCHASE SHARES OF COMMON STOCK OR EXCHANGE WARRANTS Imunon, INC. Warrant Initial Shares: [●] _________ Exercise Date: [●], 2026 THIS TRANCHE [A][B][C][D] WARRANT TO PURCHASE SHARES OF COMMON STOCK OR EXCHANGE WARRANTS (the “ Warrant ”) certifies that, for value received, [●] or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se…
Read attachment ↗ex4-9.htm · S-1/A · 2026-10-28
Exhibit 4.9 PREFUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Initial Shares: ________ Exercise Date: [●], 2026 THIS PREFUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “ Warrant ”) certifies that, for value received, [●] or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “ Initial Exercise Date ”) and…
Read attachment ↗ex107.htm · S-1 · 2026-10-27
Calculation of Filing Fee Tables S-1 Imunon, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title …
Read attachment ↗ex99-1.htm · 8-K · 2026-10-21
Exhibit 99.1 IMUNON Announces Strategic Sale of ThermoDox® Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON’s Commitment to Its Core Strategy: Executing the Pivotal Phase 3 OVATION 3 Trial of IMNN-001 LAWRENCEVILLE, N.J., October 21, 2026 - IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, …
Read attachment ↗